Hims & Hers Health Inc. (HIMS) plunged over 25% in Tuesday's pre-market session, following the FDA's decision to remove the popular weight loss drugs Wegovy and Ozempic from the shortage list last week.
The telehealth company has been a major beneficiary of selling compounded alternatives to these drugs when they were in short supply. However, with the shortage now resolved, compounding pharmacies that supplied Hims & Hers will be forced to halt production of the knockoffs by May 22nd.
This development has cast doubt on Hims & Hers' ability to sustain the robust growth in its weight loss drug business, which was a key revenue driver. While the company plans to transition to offering oral weight loss solutions and generic liraglutide, analysts remain skeptical about its lofty 2025 sales forecast for the segment, citing concerns over slower adoption of the new offerings.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。